Published in Nephron Clin Pract on November 12, 2008
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol (2010) 1.39
The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis (2011) 1.26
CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis (2011) 1.20
Recent progress in the treatment of vascular calcification. Kidney Int (2010) 1.18
Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access J Urol (2010) 1.13
Phosphate and cardiovascular disease. Adv Chronic Kidney Dis (2011) 1.06
A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res (2014) 0.98
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol (2012) 0.95
Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients (2013) 0.93
Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol (2011) 0.91
Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol (2012) 0.89
A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant (2013) 0.88
Coronary artery calcification in chronic kidney disease: An update. World J Cardiol (2014) 0.88
Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. J Am Soc Nephrol (2015) 0.87
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis (2015) 0.87
The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J (2015) 0.85
Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis (2012) 0.84
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol (2015) 0.83
Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Des (2014) 0.83
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. Int J Nephrol Renovasc Dis (2009) 0.82
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. Int J Nephrol Renovasc Dis (2014) 0.81
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence. Patient Prefer Adherence (2013) 0.81
Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol (2014) 0.79
Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep (2014) 0.78
Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis (2015) 0.78
Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One (2016) 0.76
Design and baseline characteristics of the LANDMARK study. Clin Exp Nephrol (2016) 0.75
Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. PLoS One (2017) 0.75
Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease. Semin Dial (2015) 0.75
Effects of the Use of Non-Calcium Phosphate Binders in the Control and Outcome of Vascular Calcifications: A Review of Clinical Trials on CKD Patients. Int J Nephrol (2011) 0.75
The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. PLoS One (2017) 0.75
Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol (2015) 0.75
Practical use of sevelamer in chronic kidney disease patients on dialysis in People's Republic of China. Ther Clin Risk Manag (2015) 0.75
Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia (2011) 0.75
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation (2009) 3.98
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Uric acid: A marker of increased cardiovascular risk. Atherosclerosis (2008) 2.23
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis (2013) 1.84
Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int (2005) 1.82
Comparison of skinfold thicknesses and bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body fat in patients on long-term haemodialysis therapy. Nephrol Dial Transplant (2003) 1.76
Physical activity and energy expenditure in haemodialysis patients: an international survey. Nephrol Dial Transplant (2011) 1.74
Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.60
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis (2012) 1.58
Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology (2004) 1.58
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res (2012) 1.55
Increased level of cardiorespiratory fitness blunts the inflammatory response in metabolic syndrome. Int J Cardiol (2005) 1.45
The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant (2006) 1.44
Delayed heart rate recovery is strongly associated with early and late-stage prehypertension during exercise stress testing. Am J Hypertens (2013) 1.43
Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study. PLoS One (2013) 1.39
Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol (2011) 1.36
Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health (2014) 1.31
Effect of low-power GaAlAs laser (660 nm) on bone structure and cell activity: an experimental animal study. Lasers Med Sci (2003) 1.28
Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol (2010) 1.26
Waist circumference and visceral fat in CKD: a cross-sectional study. Am J Kidney Dis (2008) 1.22
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
Subclinical coronary atherosclerosis: racial profiling is necessary! Am Heart J (2006) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int (2004) 1.16
Guideline for minimizing radiation exposure during acquisition of coronary artery calcium scans with the use of multidetector computed tomography: a report by the Society for Atherosclerosis Imaging and Prevention Tomographic Imaging and Prevention Councils in collaboration with the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr (2011) 1.15
Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract (2010) 1.14
[Quality of life in chronic renal disease patients submitted to hemodialysis evaluated with SF-36 instrument]. Rev Assoc Med Bras (2003) 1.13
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation (2015) 1.13
Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. Shock (2003) 1.10
Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study. J Am Coll Cardiol (2004) 1.08
Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery (2007) 1.07
Lipid-lowering treatment for homozygous familial hypercholesterolaemia. Lancet (2013) 1.05
Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis (2008) 1.05
Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis (2009) 1.04
The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl (2003) 1.03
Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant (2008) 1.03
Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant (2011) 1.02
Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. J Bone Miner Metab (2008) 1.01
Association of body mass index, metabolic syndrome, and leukocyte count. Am J Cardiol (2006) 1.01
Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. Nephrol Dial Transplant (2004) 0.99
Hepatic steatosis is associated with a greater prevalence of coronary artery calcification in asymptomatic men. Atherosclerosis (2007) 0.99
Double disruption of α2A- and α2C-adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype. J Bone Miner Res (2011) 0.98
Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant (2005) 0.98
Comparative study of how low-level laser therapy and low-intensity pulsed ultrasound affect bone repair in rats. Photomed Laser Surg (2006) 0.98
Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin? PLoS One (2013) 0.95
The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int (2007) 0.94
Vitamin D status in a sunny country: where has the sun gone? Clin Nutr (2010) 0.93
Ankle-brachial index: a simple way to predict mortality among patients on hemodialysis--a prospective study. PLoS One (2012) 0.93
Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone (2008) 0.93
The thyroid hormone receptor beta-specific agonist GC-1 selectively affects the bone development of hypothyroid rats. J Bone Miner Res (2004) 0.92
Family history of coronary heart disease and markers of subclinical cardiovascular disease: where do we stand? Atherosclerosis (2013) 0.92
Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab (2003) 0.92
Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol (2004) 0.92
Assessment of body composition by dual energy X-ray absorptiometry, skinfold thickness and creatinine kinetics in chronic kidney disease patients. Nephrol Dial Transplant (2004) 0.91
Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res (2010) 0.91
Nutritional parameters and mortality in incident hemodialysis patients. J Ren Nutr (2006) 0.91
Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am J Clin Nutr (2005) 0.91
Comparison of three methods for the determination of body fat in patients on long-term hemodialysis therapy. J Am Diet Assoc (2003) 0.90
Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis (2011) 0.90
No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia. Atherosclerosis (2008) 0.89
High-normal fasting blood glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men. Atherosclerosis (2007) 0.88
Relation of aortic valve calcium detected by cardiac computed tomography to all-cause mortality. Am J Cardiol (2010) 0.88
Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. Am J Cardiol (2005) 0.88
Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetol Metab Syndr (2010) 0.88
Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant (2013) 0.87
Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis (2004) 0.87
Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol (2012) 0.87
Brazilian normal static bone histomorphometry: effects of age, sex, and race. J Bone Miner Metab (2007) 0.86
Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr Med Res Opin (2010) 0.86
Decreased resting energy expenditure in non-dialysed chronic kidney disease patients. Nephrol Dial Transplant (2004) 0.86
Cardiovascular and metabolic syndrome risk among men with and without erectile dysfunction: case-control study. Sao Paulo Med J (2010) 0.86
Impact of fitness versus obesity on routinely measured cardiometabolic risk in young, healthy adults. Am J Cardiol (2013) 0.86
Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol (2014) 0.86
Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. J Bone Miner Res (2010) 0.86
Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant (2007) 0.86
A model for improving quality in nephrology settings. Nephrol Nurs J (2003) 0.86
Obesity and its association with other cardiovascular risk factors in school children in Itapetininga, Brazil. Arq Bras Cardiol (2009) 0.86
The association of subclinical coronary atherosclerosis with abdominal and total obesity in asymptomatic men. Prev Cardiol (2005) 0.86